301 related articles for article (PubMed ID: 7796869)
41. Effect of the anticonvulsant U-54494A on cortical neuron excitability: comparison to the kappa agonist U-50488H.
Ochoa MC; Vogelsang GD; Lum JT; VonVoigtlander PF; Piercey MF
Life Sci; 1992; 50(17):1225-33. PubMed ID: 1349150
[TBL] [Abstract][Full Text] [Related]
42. Reversal by kappa-agonists of peritoneal irritation-induced ileus and visceral pain in rats.
Friese N; Chevalier E; Angel F; Pascaud X; Junien JL; Dahl SG; Riviere PJ
Life Sci; 1997; 60(9):625-34. PubMed ID: 9048965
[TBL] [Abstract][Full Text] [Related]
43. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
44. [Comparative studies on the affinities of K-II and U-50488H for kappa opiate receptor].
Li JG; Ma SC; Lu SN; Wang CQ
Yao Xue Xue Bao; 1991; 26(1):10-4. PubMed ID: 1653514
[TBL] [Abstract][Full Text] [Related]
45. Modulation of thymidine incorporation by kappa-opioid ligands in rat spinal cord-dorsal root ganglion co-cultures.
Barg J; Nah SY; Levy R; Saya D; Vogel Z
Brain Res; 1993 Nov; 629(1):109-14. PubMed ID: 8287265
[TBL] [Abstract][Full Text] [Related]
46. Effect of thyrotropin releasing hormone on U-50,488H-induced pharmacological responses in mice.
Bhargava HN; Thorat SN
Brain Res; 1993 Oct; 625(1):120-4. PubMed ID: 8242390
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of the expression of ornithine decarboxylase by some kappa-opioidergic receptor ligands in difluoromethylornithine-resistant L1210 cells.
Flamigni F; Stefanelli C; Stanic I; Muscari C; Giaccari A; Rossoni C
Biochim Biophys Acta; 1996 May; 1311(3):204-10. PubMed ID: 8664348
[TBL] [Abstract][Full Text] [Related]
48. An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins.
Goode TL; Raffa RB
Life Sci; 1997; 60(7):PL107-13. PubMed ID: 9042382
[TBL] [Abstract][Full Text] [Related]
49. The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells.
Tallent M; Dichter MA; Bell GI; Reisine T
Neuroscience; 1994 Dec; 63(4):1033-40. PubMed ID: 7700508
[TBL] [Abstract][Full Text] [Related]
50. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
51. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.
Culpepper-Morgan JA; Holt PR; LaRoche D; Kreek MJ
Life Sci; 1995; 56(14):1187-92. PubMed ID: 7475895
[TBL] [Abstract][Full Text] [Related]
52. ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
Lohmann AB; Welch SP
Eur J Pharmacol; 1999 Dec; 385(2-3):119-27. PubMed ID: 10607867
[TBL] [Abstract][Full Text] [Related]
53. A pertussis toxin-sensitive G protein mediates inhibition by morphine of spontaneous electrical activity of oxytocin neurones in anaesthetized rats.
Pumford KM; Leng G; Russell JA
Exp Brain Res; 1993; 94(2):247-51. PubMed ID: 8359240
[TBL] [Abstract][Full Text] [Related]
54. Different G proteins mediate the opioid inhibition or enhancement of evoked [5-methionine]enkephalin release.
Gintzler AR; Xu H
Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4741-5. PubMed ID: 1828885
[TBL] [Abstract][Full Text] [Related]
55. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
56. Kappa-opioid peptide receptor stimulation increases cytosolic pH and myofilament responsiveness to Ca2+ in cardiac myocytes.
Ventura C; Capogrossi MC; Spurgeon HA; Lakatta EG
Am J Physiol; 1991 Nov; 261(5 Pt 2):H1671-4. PubMed ID: 1659231
[TBL] [Abstract][Full Text] [Related]
57. Differential cardiovascular and renal responses produced by microinjection of the {kappa}-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus.
Gottlieb HB; Varner KJ; Kenigs VA; Cabral AM; Kapusta DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):678-85. PubMed ID: 15381735
[TBL] [Abstract][Full Text] [Related]
58. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine.
Takahashi M; Senda T; Kaneto H
Eur J Pharmacol; 1991 Aug; 200(2-3):293-7. PubMed ID: 1664330
[TBL] [Abstract][Full Text] [Related]
59. Kappa-opioid receptor modulation of nicotine-induced behaviour.
Hahn B; Stolerman IP; Shoaib M
Neuropharmacology; 2000 Oct; 39(13):2848-55. PubMed ID: 11044755
[TBL] [Abstract][Full Text] [Related]
60. Biochemical and functional interactions of a selective kappa opioid agonist with calcium.
VonVoigtlander PF; Ochoa MC; Lewis RA
Adv Exp Med Biol; 1987; 221():345-55. PubMed ID: 2829584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
